Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Benmelstobart in Differentiated Thyroid Cancer
NCT07193186Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of benmelstobart in differentiated thyroid cancer (DTC), sponsored by Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT07193186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193186.